IFPMA 2014 interview Series: Andrew Jenner’s take on ‘Value of innovation’
In this video, Andrew Jenner, IFPMA’s Executive Director, Corporate Strategy & Legal Affairs, gives the pharmaceutical industry perspective on innovation. Despite the growing scientific, intellectual property and regulatory challenges of the past decades, over 340 new drugs have been introduced since 2002 to treat different chronic and non-chronic diseases. This can be considered as a big success story. Watch the video to find out why.
Jenner’s take is essentially based on the value of innovation from two dimensions: clinical and economic. These two dimensions are well demonstrated in two recently launched studies in 2014: the first, carried out by Charles River Associates, Assessing the value of biopharmaceutical innovation in key therapy areas in middle-income countries. The latter is evidenced by WifOR’s “First steps towards measuring the economic footprint of the industry”. To find out more about our organization: www.ifpma.org
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
Related news and resources
#AlwaysInnovating: Pharmaceutical Industry Facts & Figures
This compendium of facts and figures aims to provide a snapshot of the contribution of the pharmaceutical industry. Pharmaceutical companies are at the forefront of developing medicines and vaccines that change how we fight and prevent disease and help solve today’s biggest health challenges. In addition to their contribution to healthier societies, pharmaceutical companies also...
Read more
WIPO Standing Committee on Patents: Statement on Technology Transfer
On 16 October 2024 in Geneva, IFPMA delivered a statement at the 36th meeting of WIPO’s Standing Committee on Patents:, on technology transfer.
Read moreWIPO Standing Committee on Patents: Statement on Patents and Health
On 16 October 2024 in Geneva, IFPMA delivered a statement at the 36th meeting of WIPO’s Standing Committee on Patents: Patents and Health.
Read more